Nalaganje...
Efficacy and Safety of Adalimumab in Crohn's Disease
Adalimumab (ADA) is a subcutaneously (SC) self-administered fully human Ig G1 monoclonal antibody directed against tumor necrosis factor alpha (TNFce). In the CLASSIC dose-ranging trial, ADA was superior to placebo for inducing remission in patients with moderate-to-severe Crohn's disease (CD)...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2008
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3002485/ https://ncbi.nlm.nih.gov/pubmed/21180513 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X08092548 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|